Development and evaluation of deuterated [18F]JHU94620 isotopologues for the non-invasive assessment of the cannabinoid type 2 receptor in brain

Abstract

Abstract Background The cannabinoid type 2 receptors (CB2R) represent a target of increasing importance in neuroimaging due to its upregulation under various neuropathological conditions. Previous evaluation of [18F]JHU94620 for the non-invasive assessment of the CB2R availability by positron emission tomography (PET) revealed favourable binding properties and brain uptake, however rapid metabolism, and generation of brain-penetrating radiometabolites have been its main limitations. To reduce the bias of CB2R quantification by blood–brain barrier (BBB)-penetrating radiometabolites, we aimed to improve the metabolic stability by developing -d 4 and -d 8 deuterated isotopologues of [18F]JHU94620. Results The deuterated [18F]JHU94620 isotopologues showed improved metabolic stability avoiding the accumulation of BBB-penetrating radiometabolites in the brain over time. CB2R-specific binding with K D values in the low nanomolar range was determined across species. Dynamic PET studies revealed a CB2R-specific and reversible uptake of [18F]JHU94620-d 8 in the spleen and to a local hCB2R(D80N) protein overexpression in the striatal region in rats. Conclusion These results support further investigations of [18F]JHU94620-d 8 in pathological models and tissues with a CB2R overexpression as a prerequisite for clinical translation.

Keywords

• Cannabinoid type 2 receptor
• [18F]JHU94620
• Neuroinflammation
• Positron emission tomography